Exenatide is the active ingredient in BYETTA (R) (exenatide) injection, which is currently available in the U.S. and in many countries worldwide for people with type 2 diabetes who are unable to ...

Treatment with the diabetes drug exenatide was associated with a significant decrease in hyperglycemia in acute stroke patients, a new study shows. The research could offer clinicians an ...

Exenatide, or Byetta, is a synthetic peptide that acts at the receptor for GLP-1 – a hormone that is made in the gastrointestinal track that stimulates insulin secretion and also decreases the ...

Background: exenatide Exenatide is an incretin mimetic, i.e. it mimics the effects of an incretin produced in the body, GLP-1. Incretins are hormones that are produced in the gastrointestinal tract.

Exenatide has not been approved for use in Europe. The 26-week, open-label, randomized, two-group, parallel trial was conducted in 82 outpatient centers in 13 countries.

Exenatide is a GLP-1 agonist. Co-lead author on the new study, Tom Foltynie, says these findings certainly help add weight to the link between type 2 diabetes and Parkinson’s disease.

Exenatide, a drug commonly prescribed to help patients with type 2 diabetes improve blood sugar control, also has a powerful and rapid anti-inflammatory effect, a University at Buffalo study has shown ...

Exenatide, an incretin mimetic, was approved by the Food and Drug Administration (FDA) on April 28, 2005, as adjunctive therapy to improve glycemic control in patients with type 2 diabetes ...

RESEARCH DESIGN AND METHODS: This 52-week, multicenter, parallel-arm study (primary end point: 26 weeks) randomized patients (2:2:2:1) to dulaglutide 1.5mg, dulaglutide 0.75mg, exenatide 10g, or ...

The FDA approved exenatide in April 2005 and it was the first incretin mimetic to hit the market. Exenatide (Byetta, Amylin) is synthetic exendin-4, which binds to and activates the pancreatic ...

Exenatide, a glucagon-like peptide-1 agonist (GLP-1 agonist) medication marketed as Byetta® and Bydureon® and used in the treatment of insulin resistance in patients with Type 2 diabetes, has ...

Exenatide, the synthetic agonist of the GLP-1 receptor, has neurotrophic and neuroprotective properties in vitro. 32 Mechanisms underlying these properties are still not completely understood.